|Bid||17.21 x 1100|
|Ask||20.00 x 1100|
|Day's Range||17.21 - 18.79|
|52 Week Range||17.21 - 56.70|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,.
Portola Pharmaceuticals, Inc.'s (NASDAQ:PTLA): Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other Read More...
The company's struggling to make the shift to commercial-stage biotech, and recent news raises questions on when this will change.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. That day, the stock price closed at $20.89, which is a ~63% fall from its 52-week high of $56.70 on December 21, 2017. The stock price fell from $48.68 at the close of the market on December 29, 2017, to $20.89 on December 10, 2018, reflecting a ~57% YTD (year-to-date) fall. Portola Pharmaceuticals hit a 52-week low of $18.18 on November 7.
Shares of Portola Pharmaceuticals Inc. slid about 6% Tuesday, after the company said a European committee has extended the review period for approval of a treatment for bleeding that has already been approved in the U.S. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has provided the company with a list of questions related to data submitted for its Ondexxya product, which is being reviewed for the reversal of the anticoagulant effects of the Factor Xa inhibitors apixaban and rivaroxaban in patients experiencing uncontrolled or life-threatening bleeding. The company has a deadline of Jan. 29 for responses, followed by a 30-day assessment period for the committee. "We will work diligently to address the Committee's questions as they review and further consider the data package supporting the MAA," Portola Chief Executive Scott Garland said in a statement. An opinion is now expected by Feb. 28 of 2019. The product was approved by the U.S. Food and Drug Administration in May and is being sold under the name Andexxa. Portola shares have fallen 60% in 2018, while the S&P 500 has fallen 0.6%.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has extended the review period for the Company’s marketing authorization application (MAA) for Ondexxya™ (andexanet alfa), and cancelled the Oral Explanation scheduled for Wednesday, December 12, 2018. The CHMP informed Portola yesterday that it will provide a list of outstanding questions related to the data package the Company submitted for Ondexxya last quarter, which will require additional responses from the Company.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant.
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 29.87% and 61.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of $1.08 per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
– Third Quarter Andexxa Product Revenues of $7.7 Million – – Company Improves Financial Expectations for 2018 Operating Expenses – – Conference Call Today at 4:30 p.m. ET –.
The Company will participate in a fireside chat at the conference, which will be webcast live and available for replay from the Investor Relations section of Portola’s website at www.portola.com. The Company will conduct one-on-one meetings with institutional investors at this conference. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases.
The stock option shall have an exercise price per share of $19.69, the closing price per share of the Company’s Common Stock on October 31, 2018, and will vest over four years, with 25 percent of the shares vesting on October 8, 2019, the one-year anniversary of the vesting commencement date, and the remaining shares vesting ratably over the subsequent 36 months, subject to Mr. Garland’s continued service with the Company. The stock option has a ten-year term and is subject to the terms and conditions of the Company’s Inducement Plan and the stock option agreement pursuant to which the option was granted. The shares subject to the restricted stock unit award shall vest in three equal annual installments over three years, with the first installment vesting on October 31, 2019, in each case subject to Mr. Garland’s continued service with the Company.
– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies – – Also Accepted: Two Posters on Andexxa® and an Oral Session.
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the.